FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.ebm
Resource TypeEvidence
IdEvidence-236552.json
FHIR VersionR6

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: Evidence 236552

version: 66; Last updated: 2025-10-07 17:12:54+0000; Language: en

Profile: ComparativeEvidence

url: https://fevir.net/resources/Evidence/236552

identifier: FEvIR Object Identifier/236552, outcomeId/313880, picoId/85789, sectionId/73212

name: End_stage_kidney_disease_from_MAGICapp_313880

title: MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk

citeAs:

MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.

status: Active

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication)ComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

RelatesTos

-TypeTarget[x]
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

assertion:

There is no important difference between GLP-1 receptor agonists and standard care.

variableDefinition

description:

Adults with type 2 diabetes with moderate CV risk

variableRole: Population

observed: Adults with type 2 diabetes and established CVD (but no CKD)

variableDefinition

description:

GroupAssignment: GLP-1 RA vs. Standard care

variableRole: Exposure

comparatorCategory: Standard care

observed: GroupAssignment: GLP-1 RA vs. Standard care

variableDefinition

description:

End-stage kidney disease

variableRole: Outcome

observed: End-stage kidney disease

synthesisType: SYSTEMATIC_REVIEW

studyDesign: randomized assignment

statistic

description:

Risk Difference -0.4% (CI95 -0.7% to -0.2%)

statisticType: risk difference

quantity: -0.004

SampleSizes

-NumberOfStudiesNumberOfParticipants
*410762

AttributeEstimates

-TypeRange
*CI95-0.007--0.002

statistic

description:

OR 0.78 (CI95 0.67 to 0.92)

statisticType: odds ratio

quantity: 0.78

SampleSizes

-NumberOfStudiesNumberOfParticipants
*410762

AttributeEstimates

-TypeRange
*CI950.67-0.92

certainty

type: Overall certainty

rating: High certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencyNOTSET
*IndirectnessNOTSET
*ImprecisionNOTSET
*Publication BiasNOTSET

Source1

{
  "resourceType": "Evidence",
  "id": "236552",
  "meta": {
    "versionId": "66",
    "lastUpdated": "2025-10-07T17:12:54.639Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://fevir.net/resources/Evidence/236552",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "236552",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "outcomeId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "313880"
    },
    {
      "type": {
        "text": "picoId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "85789"
    },
    {
      "type": {
        "text": "sectionId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "73212"
    }
  ],
  "name": "End_stage_kidney_disease_from_MAGICapp_313880",
  "title": "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk",
  "citeAs": "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "ComparativeEvidence",
            "display": "ComparativeEvidence"
          }
        ]
      }
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo": [
    {
      "type": "part-of",
      "targetReference": {
        "type": "Composition",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "assertion": "There is no important difference between GLP-1 receptor agonists and standard care.",
  "variableDefinition": [
    {
      "description": "Adults with type 2 diabetes with moderate CV risk",
      "variableRole": "population",
      "observed": {
        "reference": "Group/236533",
        "type": "Group",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-population-group-85390-85789",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Adults with type 2 diabetes and established CVD (but no CKD)"
      }
    },
    {
      "description": "GroupAssignment: GLP-1 RA vs. Standard care",
      "variableRole": "exposure",
      "comparatorCategory": "Standard care",
      "observed": {
        "reference": "EvidenceVariable/236536",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-group-assignment-85390-85789",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "GroupAssignment: GLP-1 RA vs. Standard care"
      }
    },
    {
      "description": "End-stage kidney disease",
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/236551",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-313880",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "End-stage kidney disease"
      }
    }
  ],
  "synthesisType": [
    {
      "text": "SYSTEMATIC_REVIEW"
    }
  ],
  "studyDesign": [
    {
      "coding": [
        {
          "system": "http://hl7.org/fhir/study-design",
          "code": "SEVCO:01003",
          "display": "randomized assignment"
        }
      ]
    }
  ],
  "statistic": [
    {
      "description": "Risk Difference -0.4% (CI95 -0.7% to -0.2%)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000424",
            "display": "risk difference"
          }
        ]
      },
      "quantity": {
        "value": -0.004
      },
      "sampleSize": {
        "numberOfStudies": 4,
        "numberOfParticipants": 10762
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": -0.007
            },
            "high": {
              "value": -0.002
            }
          }
        }
      ]
    },
    {
      "description": "OR 0.78 (CI95 0.67 to 0.92)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000182",
            "display": "odds ratio"
          }
        ]
      },
      "quantity": {
        "value": 0.78
      },
      "sampleSize": {
        "numberOfStudies": 4,
        "numberOfParticipants": 10762
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": 0.67
            },
            "high": {
              "value": 0.92
            }
          }
        }
      ]
    }
  ],
  "certainty": [
    {
      "type": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/certainty-type",
            "code": "Overall",
            "display": "Overall certainty"
          }
        ]
      },
      "rating": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/27834",
            "code": "RJCS-2003",
            "display": "High certainty"
          }
        ]
      },
      "subcomponent": [
        {
          "type": {
            "text": "Risk of Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Inconsistency"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Indirectness"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Imprecision"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Publication Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        }
      ]
    }
  ]
}